4-fluorocinnamic acid: RN given refers to (E)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 1530234 |
| CHEMBL ID | 99526 |
| CHEBI ID | 176440 |
| SCHEMBL ID | 81378 |
| MeSH ID | M0124419 |
| Synonym |
|---|
| CHEMBL99526 , |
| LS-13585 |
| EN300-16809 |
| (e)-3-(4-luorophenyl)prop-2-enoic acid |
| CHEBI:176440 |
| 4-fluorocinnamic acid |
| p-fluorocinnamic acid |
| 459-32-5 |
| nsc-74070 |
| nsc74070 |
| 4-fluorocinnamic acid, 99% |
| 14290-86-9 |
| (2e)-3-(4-fluorophenyl)prop-2-enoic acid |
| STK010125 |
| AC-10329 |
| HMS1396N04 |
| 3-(4-fluorophenyl)prop-2-enoic acid |
| F0244 |
| (e)-3-(4-fluorophenyl)prop-2-enoic acid |
| AKOS000120458 |
| 3-(4-fluorophenyl)acrylic acid |
| (e)-3-(4-fluorophenyl)-2-propenoic acid |
| nsc 74070 |
| einecs 207-288-9 |
| (e)-p-fluorocinnamic acid |
| einecs 238-214-3 |
| (e)-3-(4-fluorophenyl)acrylic acid |
| trans-4-fluorocinnamic acid |
| 2-propenoic acid, 3-(4-fluorophenyl)- |
| 2-propenoic acid, 3-(4-fluorophenyl)-, (2e)- |
| PS-6566 |
| F3145-1789 |
| SCHEMBL81378 |
| AB01314091-03 |
| e-3-(4-fluorophenyl)propenoic acid |
| (e)-3-(4-fluorophenyl) acrylic acid |
| e-4-fluorocinnamic acid |
| mfcd00004395 |
| W-106111 |
| bdbm50486890 |
| AC7879 |
| BCP21432 |
| 2-(2-chlorophenyl)-2h-benzo[b][1,4]thiazin-3(4h)-one |
| 4-fluorocinnamic acid; lc-tdda; ce10 |
| (e)-3-(4-fluorophenyl)acrylicacid |
| EN300-364714 |
| AMY3987 |
| A885077 |
| 4'-fluoro-4-iodobutyrophenone; 4'-fluorocinnamic acid; 4-iodo-4'-fluorobutyrophenone; |
| NCGC00338431-01 |
| (e)-3-(4-fluoro-phenyl)-acrylic acid |
| (~{e})-3-(4-fluorophenyl)prop-2-enoic acid |
| DTXSID001309863 |
| CS-W010812 |
| Z2942851074 |
| Class | Description |
|---|---|
| cinnamic acids | Any alpha,beta-unsaturated monocarboxylic acid based on the cinnamic acid skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1755148 | Larvicidal activity against Aedes aegypti assessed as mortality at 100 ug/ml measured after 24 hrs relative to control | 2021 | Bioorganic & medicinal chemistry, 08-15, Volume: 44 | Larvicidal activity and in silico studies of cinnamic acid derivatives against Aedes aegypti (Diptera: Culicidae). |
| AID37266 | Inhibition of alpha-glucosidase activity | 2004 | Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11 | Structure-activity relationships of trans-cinnamic acid derivatives on alpha-glucosidase inhibition. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.09) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||